Skip to content
Screener

Harrow HROW EPS (Diluted)

EPS (Diluted) at other companies

AbbVie logo
AbbVieABBV
$2.03+290%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$0.35+450%
Bausch + Lomb logo
Bausch + LombBLCO
-$0.04+77.8%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$0.40-5.3%
Opko Health logo
Opko HealthOPK
-$0.01+94.7%
Schering-Plough logo
Schering-PloughSGP
-$0.69+82.6%

Other financials

Income statement

See full
Revenue$70.7M+10.9%
Gross profit$50.4M+6.0%
Operating income-$11.0M-196%
Net income-$17.3M-446%

Balance sheet

See full
Cash & equivalents$83.9M+58.4%
Total debt$308.4M-32.0%
Total equity$15.2M-69.4%
Total assets$416.8M+20.8%

Cash flow

See full
Operating cash flow-$9.8M—
CapEx$491.0K+196%
Free cash flow-$10.2M—

Valuation

See full
Market cap$1.15B-35.0%
Enterprise value$1.37B-33.7%
P/S4.2×-2.9×

Profitability

See full
Gross margin73.3%-1.3pp
Operating margin-1%-7.3pp
Net margin-19.8%+18.0pp
FCF margin1.8%+1.3pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity20.3×+11.2×
Current ratio2.2×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Harrow’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-055271
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Other (expense) income, net—(6,000)—(6,000)
(Loss) income before income taxes(17,270,000)4,995,000(44,847,000)(12,785,000)
Income tax expense——(25,000)—
Net (loss) income$(17,270,000)$4,995,000$(44,872,000)$(12,785,000)
Basic net (loss) income per share of common stock$(0.46)$0.14$(1.20)$(0.35)
Diluted net (loss) income per share of common stock$(0.46)$0.13$(1.20)$(0.35)
Weighted average number of shares of common stock outstanding, basic37,350,40136,790,30637,291,19036,304,787
Weighted average number of shares of common stock outstanding, diluted37,350,40138,853,85537,291,19036,304,787

Item 1. Financial Statements

FAQ

What is Harrow's EPS (diluted)?
Harrow (HROW) reported EPS (diluted) of -$0.46 in Q2 2026.
How has Harrow's EPS (diluted) changed year-over-year?
Harrow's EPS (diluted) decreased by 453.8% year-over-year, from $0.13 to -$0.46.
What is the long-term trend for Harrow's EPS (diluted)?
Over 2 years (2021 to 2023), Harrow's EPS (diluted) has grown at a 5.7% compound annual growth rate (CAGR), from -$0.68 to -$0.76.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Harrow's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude